Barr, Par settle dispute with Valeant |
|
|
|
Published
:
Mon, 15 Oct 2007 13:52
|
NEW YORK (AP) - Generic drug developers Barr Laboratories Inc. and Par Pharmaceutical Companies Inc. said Monday they settled a patent dispute over the Diastat at-home epileptic seizure treatments with Valeant Pharmaceuticals International.Valeant holds the patent for the treatments. Under the agreement, Barr will have the right to launch a generic version of Diastat and Diastat AcuDial on or after Sept. 1, 2010. Barr will record the sales and split the profits with Par.The patent challenge was initiated by Kali Laboratories Inc., which Par has since acquired.Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
|
|
|
|
Print this Story
Barr Pharma former COO exercises options 